Moberg pharma joins hands with Allderma to enter the market with a new nail fungus product named MOB-015.
Moberg Pharma will cover the manufacturing and delivery of the nail fungus product, while its partner will undertake the tasks of marketing the drug, completing its sale as well as distribution. The Moberg Pharma collaboration with Allderma is set to launch in Scandinavia.
The agreement between the two parties contains financial terms which are market-based and builds upon the licensing agreement the company already acquired. Allderma has had success with launching nail fungus products before as well. An example of such a product is Nalox, another Moberg Pharma collaboration with Allderma.
A Moberg official stated that the company would like to repeat the success of Nalox, which had seen a growth rate of 400% in a similar region. In fact, MOB-015 shows even more promise than Nalox.
As Allderma launches the nail product in Scandinavia, an official from the company detailed its unique features. MOB-15 is earliest in the market for this kind of topical antifungal medicine that does not pose a threat for significant side effects, and boasts an efficacy equal to oral drugs for the same purpose.
